New Perspectives in the Therapy of Castration Resistant Prostate Cancer
Abstract
Prostate Cancer is the most commonly diagnosed malignancy and the second leading cause of cancer-related death in men in the Western World. Docetaxel-based chemotherapy has been the mainstay of treatment until a few years ago for metastatic castration resistant prostatic cancer (mCRPC). Recently, a broad range of therapeutic options has become available for mCRPC in a variety of settings, including chemotherapeutic agents (cabazitaxel), androgen synthesis inhibitors (abiraterone acetate), androgen receptor (AR) inhibitors (enzalutamide) and immunotherapy (sipuleucel-T). Multiple novel targeted agents are at an advanced stage of experimentation, including androgen synthesis inhibitors (TAK700), AR inhibitors (ARN509), radiopharmaceuticals (radium-223) and immunotherapeutic agents (poxvirus-based vaccine, ipilimumab). This review describes in detail the latest results obtained with a the most promising agents in prostate cancer, with a focus on CRPC biology and mechanism of resistance to anti-neoplastic treatment.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
As a combination regimen, bortezomib did not improve prostate cancer patients' response to docetaxel.
“As a combination regimen, bortezomib was found not able to improve prostate cancer patients’ response to docetaxel, a standard treatment for mCRPC (5, 6).”
From miR-33b-3p Acts as a Tumor Suppressor by Targeting DOCK4 in Prostate Cancer (2021) · cites this paper as [6]
Cited by
Sorted by citations
miR-33b-3p Acts as a Tumor Suppressor by Targeting DOCK4 in Prostate Cancer
Mei, Y., Li, K., Zhang, Z., Li, M., Yang, H., Wang, H., Huang, X., Li, X., Shi, S., & Yang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.740452 · Cited by 10 · see citing works
“As a combination regimen, bortezomib was found not able to improve prostate cancer patients’ response to docetaxel, a standard treatment for mCRPC (5, 6).”
Background
- Authors
- Rescigno, P., Buonerba, C., Bellmunt, J., Sonpavde, G., De Placido, S., & Di Lorenzo, G.
- Affiliations
- Federico II University Hospital (IT)
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-10-01
- Volume
- 13
- Issue
- 13
- Pages
- 1676-1686
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2169091599
- Cited by
- 37
- References
- 0
- Citations by year
- 2023: 1 · 2022: 2 · 2021: 5 · 2020: 1 · 2019: 1 · 2017: 2 · 2016: 5 · 2015: 1 · 2014: 8 · 2013: 11
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, docetaxel, cabazitaxel, abiraterone, enzalutamide, sipuleucel-T, radium-223, androgen receptor antagonists, androgen synthesis inhibitors, immunotherapy, targeted therapy, hormone therapy, chemotherapy, treatment resistance, ipilimumab
- MeSH terms
- Androgen Antagonists, Animals, Antineoplastic Agents, Clinical Trials as Topic, Humans, Male, Orchiectomy, Prostatic Neoplasms, Radiopharmaceuticals, Cancer Vaccines, Taxoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
